Anti-CD38 antibody - Mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

Blood

Volumn 112, Issue 3, 2008, Pages 568-575

  Taussig, David C ^a,b,d   Miraki Moud, Farideh ^a   Anjos Afonso, Fernando ^b   Pearce, Daniel J ^b   Allen, Kirsty ^b   Ridler, Christopher ^b   Lillington, Debra ^a   Oakervee, Heather ^a   Cavenagh, Jamie ^a   Agrawal, Samir G ^a   Lister, T Andrew ^a   Gribben, John G ^a   Bonnet, Dominique ^b,c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c CRUK London Research Institute   (United Kingdom)

^d Medical Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; CD38 ANTIBODY; CELL ANTIBODY; FC RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; CD34 ANTIGEN; CD38 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL HETEROGENEITY; CELL POPULATION; CONTROLLED STUDY; DRUG ACTIVITY; ENGRAFTMENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOLOGY; DRUG EFFECT; FETUS BLOOD; GRAFT SURVIVAL; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY;

ANIMALS; ANTIBODIES; ANTIGENS, CD34; ANTIGENS, CD38; CELLS, CULTURED; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; GRAFT SURVIVAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION;

EID: 50949090415     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-118331     Document Type: Article

References (25)

1. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A. 1997;94:5320-5325.
2. Civin CI, Almeida-Porada G, Lee MJ, Olweus J, Terstappen LW, Zanjani ED. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood. 1996;88:4102-4109.
3. Hogan CJ, Shpall EJ, Keller G. Differential longterm and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCI D mice. Proc Natl Acad Sci U S A. 2002;99:413-418.
4. McKenzie JL, Gan OI, Doedens M, Wang JC, Dick JE. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol. 2006;7:1225-1233.
5. Blair A, Hogge DE. Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997; 89:3104-3112.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
7. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315-1321.
8. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180-191.
9. Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005; 106:4086-4092.
10. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCI D assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107: 1166-1173.
11. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
12. Ellis JH, Barber KA, Tutt A, et al. Engineered antiCD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol. 1995:155:925-937.
13. Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an antiinterleukin 2 receptor beta chain monoclonal antibody in mice. J Exp Med. 1993;178:1103-1107.
14. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med. 2006;12:688-692.
15. McKenzie JL, Gan OI, Doedens M, Dick JE. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD 122+ cells. Blood. 2005;106:1259-1261.
16. Yahata T, Ando K, Sato T, et al. A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow. Blood. 2003;101:2905-2913.
17. Krause DS, Theise ND, Collector MI, et al. Multiorgan, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001 ;105:369-377.
18. Chou WC. Tang JL, Wu SJ, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leu-kemia patients bearing nucleophosmin (NPM1) mu-tations. Leukemia. 2007;21:9981004.
19. Jordan GT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
20. Bonnet D, Bhatia M, Wang JC, Kapp U, Dick JE. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant. 1999;23:203-209.
21. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623-2634.
22. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738-743.
23. Castor A, Nilsson L. Astrand-Grundstrom I. et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med. 2005;11:630-637.
24. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17:3029-3035.
25. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316: 600-604.